|
|
||||||||||
|
J Am Coll Cardiol, 2008; 51:1188-1195, doi:10.1016/j.jacc.2007.11.054 © 2008 by the American College of Cardiology Foundation |





* Kerckhoff Heart Center, Bad Nauheim, Germany
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Centro de Educacion Medica e Investigative Clinicas, Buenos Aires, Argentina
Instituto Cardiovascular Buenos Aires, Buenos Aires, Argentina.
Manuscript received August 6, 2007; revised manuscript received October 2, 2007, accepted November 8, 2007.
* Reprint requests and correspondence: Dr. Michael W. Weber, Kerckhoff Heart Center, Department of Cardiology, Benekestraβe 2-8, 61231 Bad Nauheim, Germany. (Email: M.Weber{at}Kerckhoff-Klinik.de).
Objectives: The purpose of this study was to determine the prognostic value of N-terminal B-type natriuretic peptide (NT-proBNP) in two independent samples of patients presenting with acute coronary syndromes (ACS) and normal troponin T (TnT) values.
Background: Recently assessment of NT-proBNP has been studied in patients with ACS. However, the clinical relevance in patients who present without troponin elevation is unclear.
Methods: We included 2,614 patients from two independent registries, one serving as a derivation cohort comprising patients with evident ACS (Bad Nauheim ACS registry, n = 1,131) and the other serving as a validation cohort including chest pain patients (PACS [Prognosis in Acute Coronary Syndromes] registry, n = 1,483). NT-proBNP and TnT were measured upon admission. Clinical outcome has been assessed over a 6-month period.
Results: In both cohorts, the mortality rate was significantly lower among TnT negative patients: 3.8% versus 8.2% (p = 0.009) in the Bad Nauheim ACS registry, and 2.8% versus 8.6% (p = 0.009) in the PACS registry. Among TnT negative patients, receiver-operating characteristics curve analysis yielded an optimal cutoff value of 474 pg/ml for NT-proBNP that was able to discriminate patients at higher risk in the Bad Nauheim ACS and PACS registries (mortality rate 12.3% vs. 1.3%, p < 0.001 and 8.5% vs. 1.5%, p < 0.001, respectively). By Kaplan-Meier analysis, patients with NT-proBNP values over 474 pg/ml were at higher risk for death in the Bad Nauheim ACS registry (log-rank 19.01, p < 0.001, adjusted hazard ratio [HR] 9.56 [95% confidence interval (CI) 2.42 to 37.7], p = 0.001) and in the PACS registry (log-rank 23.16, p < 0.001, adjusted HR 5.02 [95% CI 2.04 to 12.33], p < 0.001).
Conclusions: Among patients with suspected ACS considered to be at low risk because of normal troponin values, NT-proBNP above 474 pg/ml is able to discriminate individuals at higher risk. Because of its incremental prognostic value, NT-proBNP assessment should be considered in clinical routine for risk stratification of patients with normal troponin.
| ||||||||||||||||
Related articles in JACC:
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |